Inhibrx Advances Ozekibart Toward FDA Decision as PFS Data in HNSCC Looms
核心洞察
Inhibrx reported a $36.7 million net loss for Q2 2026, up from $28.7 million a year earlier, driven by BLA-preparation manufacturing costs and pre-launch spending.
The FDA accepted the biologics license application for ozekibart in conventional chondrosarcoma (搜索) and set a PDUFA goal date of April 14, 2027.
Inhibrx plans to announce progression-free survival data from the randomized Phase 2 trial of INBRX-106 in head and neck squamous cell carcinoma (搜索) in Q3 2026.
Inhibrx Biosciences, Inc. (Nasdaq: INBX) reported second quarter 2026 financial results on August 13, 2026, as the clinical-stage biopharmaceutical company advances two programs through ongoing clinical trials and steers its lead asset, ozekibart (INBRX-109), toward a potential first regulatory approval. The quarter was defined by a $36.7 million net loss, up from $28.7 million a year earlier, driven largely by biologics license application (BLA)-preparation manufacturing costs and pre-launch market access spending.
Regulatory Milestone for Ozekibart in Chondrosarcoma
In June 2026, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's BLA for the potential approval of ozekibart in conventional chondrosarcoma (搜索) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027. Chondrosarcoma is a disease long managed without an approved drug specifically targeting the indication, which helps explain the Company's decision to build commercial infrastructure ahead of approval. General and administrative expenses rose to $8.3 million during the second quarter of 2026, compared to $6.4 million in the prior-year period, an increase primarily related to additional pre-commercialization expenses for market access, launch, and the development of communication materials as Inhibrx prepares for potential commercialization of ozekibart in conventional chondrosarcoma.
Expanding the Colorectal Cancer Program
During the second quarter of 2026, Inhibrx initiated two additional Phase 1 cohorts in colorectal cancer (搜索) (CRC): a second-line study investigating ozekibart in combination with Folfiri and Avastin, and a third/fourth-line study investigating ozekibart in combination with Lonsurf and Avastin. The Company expects to announce interim results from these cohorts during the first quarter of 2027.
The Company plans to meet with the FDA in the fourth quarter of 2026 to discuss plans to initiate a first-line registrational trial in CRC as well as the potential for an accelerated regulatory pathway for ozekibart in fourth-line CRC. The interim data from the two new CRC cohorts, expected in Q1 2027, are timed to inform what Inhibrx asks the agency for in that meeting.
INBRX-106 and the Near-Term PFS Readout
The Company's second program, INBRX-106, adds a near-term binary to the calendar. Inhibrx plans to announce progression-free survival (PFS) data from the randomized Phase 2 trial in head and neck squamous cell carcinoma (搜索) (HNSCC) in combination with pembrolizumab in the third quarter of 2026. Earlier interim data from the randomized Phase 2 trial in PD-L1-positive HNSCC showed a confirmed objective response rate numerically higher than pembrolizumab monotherapy. PFS, rather than response rate, is the endpoint that moves regulatory conversations forward given that pembrolizumab is well established in this setting.
Financing and Financial Position
In July 2026, the Company entered into a second amendment to its Loan and Security Agreement with Oxford Finance LLC (搜索), providing for an additional $325.0 million in gross proceeds, of which $100.0 million was funded upon execution and up to an additional $225.0 million may be funded in future increments of $50.0 million or more at the Company's request and Oxford's discretion.
As of June 30, 2026, the Company had cash and cash equivalents of $133.3 million. Following receipt of the $100.0 million gross proceeds on July 15, 2026, the Company held cash and cash equivalents of $219.5 million as of August 6, 2026.
Research and development expenses were $23.9 million for the second quarter of 2026, compared to $22.3 million for the second quarter of 2025, an increase primarily related to higher clinical trial costs and contract manufacturing expenses as the Company progresses its ongoing trials and begins manufacturing activities to support the BLA filing for ozekibart in conventional chondrosarcoma (搜索). Other expense, net was $4.5 million during the second quarter of 2026, compared to $1.3 million a year earlier, primarily due to higher interest expense on the Company's $175.0 million outstanding loan balance. Net loss was $36.7 million, or $2.34 per share, basic and diluted, compared to a net loss of $28.7 million, or $1.85 per share, in the second quarter of 2025.
Pipeline and Outlook
Inhibrx is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, utilizing diverse methods of protein engineering including its proprietary platforms. Its current clinical pipeline includes ozekibart and INBRX-106, both of which use multivalent formats where precise valency can be optimized in a target-centric way to mediate what the Company believes to be the most appropriate agonist function.
The convergence of regulatory, clinical, and financing milestones arriving in rapid succession makes the coming quarters pivotal. The single number to track, according to industry observers, is the PFS hazard ratio in HNSCC expected in the third quarter of 2026, which could reshape Inhibrx's negotiating position on partnership discussions and the scope of what it can reasonably request from the FDA for ozekibart in CRC.